Published in Mediators Inflamm on February 21, 2016
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol (2009) 11.63
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature (2005) 6.83
Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med (1990) 4.90
Other functions, other genes: alternative activation of antigen-presenting cells. Immunity (1999) 4.15
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
The EGF-TM7 family: a postgenomic view. Immunogenetics (2003) 1.27
Involvement of vitronectin in lipopolysaccaride-induced acute lung injury. J Immunol (2007) 1.26
Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol (2000) 1.18
LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res (2011) 1.15
Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res (2000) 1.14
The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J Immunol (2004) 1.14
Resolving the Two "Bony" Faces of PPAR-gamma. PPAR Res (2006) 1.09
Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol (2002) 1.09
CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res (1997) 1.07
Characterization of an early activation-dependent antigen on lymphocytes defined by the monoclonal antibody BL-Ac(F2). Scand J Immunol (1994) 1.03
Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol (2004) 1.00
EGF-TM7: a novel subfamily of seven-transmembrane-region leukocyte cell-surface molecules. Immunol Today (1996) 1.00
Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens (2001) 0.99
Thy-1 (CD90) is an interacting partner for CD97 on activated endothelial cells. J Immunol (2011) 0.96
Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes. J Hypertens (2012) 0.94
Lipopolysaccharide-induced tumor necrosis factor-alpha promoter activity is inhibitor of nuclear factor-kappaB kinase-dependent. J Biol Chem (1999) 0.90
CD97 isoform expression in leukocytes. J Leukoc Biol (2000) 0.82
Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB. Cell Biol Int (2010) 0.81
Chondroitin sulfate inhibits lipopolysaccharide-induced inflammation in rat astrocytes by preventing nuclear factor kappa B activation. Neuroscience (2010) 0.79
Chondroitin-6-sulfate attenuates inflammatory responses in murine macrophages via suppression of NF-κB nuclear translocation. Acta Biomater (2014) 0.79
Differential expression of the EGF-TM7 family members CD97 and EMR2 in lipid-laden macrophages in atherosclerosis, multiple sclerosis and Gaucher disease. Immunol Lett (2010) 0.78
CD97 antibody depletes granulocytes in mice under conditions of acute inflammation via a Fc receptor-dependent mechanism. J Leukoc Biol (2010) 0.77
Expression of CD97 and adhesion molecules on circulating leukocytes in patients undergoing coronary artery bypass surgery. Eur Surg Res (2005) 0.77